Drug Trial News

RSS

MD Anderson joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that MD Anderson Cancer Center in Houston, Texas has joined the Company's ongoing Phase I/II trial in newly diagnosed patients with acute myeloid leukemia (AML).

12 Sep 2012

Gene therapy regimen can safely restore immune systems to children with Bubble Boy disease

UCLA stem cell researchers have found that a gene therapy regimen can safely restore immune systems to children with so-called "Bubble Boy" disease, a life threatening condition that if left untreated can be fatal within one to two years.

12 Sep 2012

Leading dengue fever vaccine candidate 30% effective in first large clinical trial

"The leading candidate to become the world's first vaccine against dengue fever was only 30 percent effective in its first large clinical trial, dealing at least a temporary setback to efforts to control a disease that threatens half the world's population," the New York Times reports.

12 Sep 2012

Daily low-dose inhaled corticosteroids do not benefit asthmatics

For two decades, asthma treatment for millions of people with a milder form of the disease has consisted of daily inhaled steroid medicine to reduce inflammation. Now, a new study has found that asthmatics who take the low-dose medication as a daily routine do no better than those who turn to their inhalers only when they have symptoms.

12 Sep 2012

Researchers present new results from RV144 HIV vaccine trial at AIDS Vaccine 2012

"A paper published in Nature on Monday sheds light on how a vaccine can turn the immune system against [HIV] and so offer protection from infection," Nature News reports, noting "[t]he results are also being presented at the AIDS Vaccine 2012 conference in Boston, Massachusetts, this week."

12 Sep 2012

e-Therapeutics initiates second ETS2101 phase I trial in solid tumours

e-Therapeutics plc announces that it has started a second phase I clinical trial of its anti-cancer drug ETS2101. This trial will enrol up to 45 patients with a variety of solid tumours at two UK centres, St James's University Hospital in Leeds and the Northern Centre for Cancer Care at the Freeman Hospital in Newcastle.

12 Sep 2012

KaloBios commences KB003 Phase 2 trial in severe asthma

KaloBios Pharmaceuticals, Inc. today announced that dosing has begun in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of KB003, the company's anti-GM-CSF Humaneered monoclonal antibody, in subjects with severe asthma uncontrolled by corticosteroids.

12 Sep 2012

Ginkgo biloba supplements fail to improve cognitive performance in multiple sclerosis

A research study conducted by Dr. Jesus Lovera, Assistant Professor of Neurology at LSU Health Sciences Center New Orleans, and colleagues has found that the herbal supplement Ginkgo biloba does not improve cognitive function in patients with Multiple Sclerosis (MS).

12 Sep 2012

Positive results from Santarus rifamycin SV MMX Phase III study on travelers' diarrhea

Santarus, Inc. today announced that its Phase III clinical study to evaluate the safety and efficacy of the investigational drug, rifamycin SV MMX, met the primary endpoint of reducing time to last unformed stool (TLUS) in patients with travelers' diarrhea.

12 Sep 2012

GE Healthcare announces data from [18F]flutemetamol phase III studies on Alzheimer's

GE Healthcare today announced pooled results from phase III brain autopsy and biopsy studies on the investigational PET amyloid imaging agent, [18F]flutemetamol, which showed a strong concordance between [18F]flutemetamol images and Alzheimer's disease-associated beta amyloid brain pathology.

11 Sep 2012

Durata Therapeutics completes dalbavancin Phase 3 trials on ABSSSI

Durata Therapeutics today announced results from its QT study of the company's lead product candidate, dalbavancin. Dalbavancin is currently under investigation in two ongoing, global, Phase 3 clinical trials for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

11 Sep 2012

Dengue vaccine breakthrough

Results of the first ever trial to show that a safe and effective dengue vaccine may be possible are published Online First in The Lancet.

11 Sep 2012

Pergamum initiates LL-37 Phase I/II trial in hard-to-heal venous leg ulcers

Pergamum AB announced today that dosing has begun in a randomized Phase I/II trial of LL-37 for the treatment of patients with hard-to-heal venous leg ulcers.

11 Sep 2012

Data from Sangamo BioSciences’ SB-728-T Phase 1 clinical programs on HIV/AIDS

Sangamo BioSciences, Inc. announced that data from its Phase 1 clinical programs to develop SB-728-T, a novel therapeutic approach designed to generate a "functional cure" for HIV/AIDS, were presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

11 Sep 2012

Palatin Technologies completes bremelanotide Phase 2B trial on female sexual dysfunction

Palatin Technologies, Inc. today announced that the last patient has completed treatment in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction (FSD).

11 Sep 2012

Top line results from Zalicus Synavive Phase 2b study in rheumatoid arthritis

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced top line results from its randomized, double-blind, placebo-controlled, Phase 2b clinical trial of Synavive in rheumatoid arthritis.

10 Sep 2012

Atox Bio AB103 for Necrotizing Soft Tissue Infections granted FDA Fast Track designation

Atox Bio, a clinical stage biotechnology company engaged in the development of novel immunemodulators for severe infections in critically ill patients, announced today that the U.S. Food and Drug Administration has granted Fast Track designation to AB103, its lead product, currently in development for the treatment of Necrotizing Soft Tissue Infections (NSTI).

10 Sep 2012

Phase III data for Suvorexant, an investigational insomnia medicine, announced

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. The new data are from one of the longest, continuously-dosed, placebo-controlled trials of a sleep medication ever conducted.

10 Sep 2012

TauRx initiates LMTX Phase 3 trial in Pick's Disease

TauRx Therapeutics today announced the initiation of a global Phase 3 clinical trial in a type of Frontotemporal Dementia (FTD) also known as Pick's Disease. The announcement, which immediately follows The 8th International Conference on Frontotemporal Dementias, held 5-7 September in Manchester, England, underscores the need for new treatments for this form of dementia that is similar to Alzheimer's Disease, except that it tends to damage different areas of the brain and affects people as early as 40 years old.

10 Sep 2012

New oral antiseptic spray effective in killing 99.9% of infectious airborne germs

University Hospitals Case Medical Center clinical researchers will present findings about a one-two punch to prevent colds and flu in San Francisco at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) on Sept. 9.

10 Sep 2012

Drug Trial News

MD Anderson joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

Gene therapy regimen can safely restore immune systems to children with Bubble Boy disease

Leading dengue fever vaccine candidate 30% effective in first large clinical trial

Daily low-dose inhaled corticosteroids do not benefit asthmatics

Researchers present new results from RV144 HIV vaccine trial at AIDS Vaccine 2012

e-Therapeutics initiates second ETS2101 phase I trial in solid tumours

KaloBios commences KB003 Phase 2 trial in severe asthma

Ginkgo biloba supplements fail to improve cognitive performance in multiple sclerosis

Positive results from Santarus rifamycin SV MMX Phase III study on travelers' diarrhea

GE Healthcare announces data from [18F]flutemetamol phase III studies on Alzheimer's

Durata Therapeutics completes dalbavancin Phase 3 trials on ABSSSI

Dengue vaccine breakthrough

Pergamum initiates LL-37 Phase I/II trial in hard-to-heal venous leg ulcers

Data from Sangamo BioSciences’ SB-728-T Phase 1 clinical programs on HIV/AIDS

Palatin Technologies completes bremelanotide Phase 2B trial on female sexual dysfunction

Top line results from Zalicus Synavive Phase 2b study in rheumatoid arthritis

Atox Bio AB103 for Necrotizing Soft Tissue Infections granted FDA Fast Track designation

Phase III data for Suvorexant, an investigational insomnia medicine, announced

TauRx initiates LMTX Phase 3 trial in Pick's Disease

New oral antiseptic spray effective in killing 99.9% of infectious airborne germs

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News